Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is expected to see a strong increase in revenue and EPS through 2026 to 2028, with a PT target of $1,230 and an OW rating. This is likely due to their successful acquisition of CNTA and Kelonia Therapeutics, as well as a positive outlook for their current key products in the neuroscience, cardiometabolic, and immunology spaces. The 1Q26 IPR&D charge of $584M may have a slight impact on EPS, but overall, their financials and acquisitions point to a promising future for the company.

Bears say

Eli Lilly is facing significant downside risks, including potential pricing and rebate pressure, slower-than-expected growth of tirzepatide and forglipron, and underperformance of its pipeline products. Recent negative headlines regarding an unadjudicated adverse event in the company's FAERS database raise red flags, further justifying a negative outlook. With 1Q26 revenues and EPS forecasted below consensus, and LLY's 2026, 2027, and 2028 revenues and EPS projected to fall short as well, the company's financials are not supporting a positive outlook for the stock.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,236.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,236.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.